Trials / Terminated
TerminatedNCT04178902
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
A First In Human Study of the MCL-1 Inhibitor, ABBV-467
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-467 | Intravenous (IV) Infusion |
Timeline
- Start date
- 2020-05-19
- Primary completion
- 2021-04-16
- Completion
- 2021-04-16
- First posted
- 2019-11-26
- Last updated
- 2021-07-26
Locations
24 sites across 7 countries: United States, Australia, France, Israel, Japan, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04178902. Inclusion in this directory is not an endorsement.